Background

10% of the world suffers from autoimmune disorders, with there being 80-100 known autoimmune and autoimmune-related conditions, including Hashimoto’s thyroiditis, Type 1 diabetes, Sjogren’s, and celiac disease.

Anti-TNF drugs are not associated with any significant benefit for a range of inflammatory diseases including Sjogren’s syndrome, despite their proven efficacy in inflammatory arthritis. Furthermore, single cytokine-blockade is most often only efficacious for a limited time, with there being no current competitor immunotherapy offering a multi-cytokine benefit (no immunotherapy blocks multiple cytokines).

The development of immune checkpoint inhibitors (ICIs) provided revolutionary new treatment options for cancer patients. However, despite their clinical and commercial success, the majority of patients are refractory to current ICIs. As such, there is a high market interest